Arcturus Therapeutics Holdings Inc. (ARCT) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Arcturus Therapeutics Holdings Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
High 17.47 at 9:30 am ET, low 16.02 at 3:45 pm ET.
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.
the bull case· 4
4
disclosed supplier and customer ties in SEC filings
sec filingsedgar3
of the funds on file reporting a position in ARCT
n-portas of Jun 30 '26135
managers reporting a position in thirteen F filings
13fJun 30 '26+0.09%
change in shares held by the ten largest reporting managers over latest quarter
13fJun 30 '26the bear case· 4
6 of 8
recent reports where the move came in under the options implied range
earnings historyimplied vs realized0.01%
of iShares Russell two thousand ETF assets the largest fund weight on file
n-portJun 30 '268 of 24
of the largest reporting managers cut their stake in the latest quarter
13fJun 30 '2616
managers whose positions together make up four fifths of the reported value
13fJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 10 '26 report. Not a forecast, not advice.
Of the 6 companies Arcturus Therapeutics Holdings Inc. moves with most closely, none share its SEC classification.
Measured against 500 trading days of our own closes. Co-movement, not cause.
SIC 2834, Pharmaceutical Preparations, from each company's own filings. Largest first.
135 managers report a position worth $168.1M between them, and 16 of them hold 80% of it.
tall tick = annual report · 1 on record
ARCT (Arcturus Therapeutics Holdings Inc.) has 1 disclosed suppliers and 3 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.